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Abstract
Albeit genetically highly heterogeneous, muscular dystrophies (MDs) share a convergent pathology leading to muscle
wasting accompanied by proliferation of fibrous and fatty tissue, suggesting a common MD–pathomechanism. Here we
show that mutations in muscular dystrophy genes (Dmd, Dysf, Capn3, Large) lead to the spontaneous formation of skeletal
muscle-derived malignant tumors in mice, presenting as mixed rhabdomyo-, fibro-, and liposarcomas. Primary MD–gene
defects and strain background strongly influence sarcoma incidence, latency, localization, and gender prevalence.
Combined loss of dystrophin and dysferlin, as well as dystrophin and calpain-3, leads to accelerated tumor formation.
Irrespective of the primary gene defects, all MD sarcomas share non-random genomic alterations including frequent losses
of tumor suppressors (Cdkn2a, Nf1), amplification of oncogenes (Met, Jun), recurrent duplications of whole chromosomes 8
and 15, and DNA damage. Remarkably, these sarcoma-specific genetic lesions are already regularly present in skeletal
muscles in aged MD mice even prior to sarcoma development. Accordingly, we show also that skeletal muscle from human
muscular dystrophy patients is affected by gross genomic instability, represented by DNA double-strand breaks and age-
related accumulation of aneusomies. These novel aspects of molecular pathologies common to muscular dystrophies and
tumor biology will potentially influence the strategies to combat these diseases.
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Introduction
‘‘… fibres were found to be completely destroyed, the sarcous element
being diffused, and in many places converted into oil globules and
granular matter…’’
(Edward Meryon, 1852)
Muscular dystrophies (MDs) comprise a group of inherited
disorders, characterized by progressive muscle wasting and
weakness, frequently causing premature death due to lack of
effective therapies. More than 150 years ago, Edward Meryon was
the first to characterize the detrimental ‘‘fatty degeneration of the
voluntary muscles’’ in Duchenne MD (Meryon E. Lancet 2:588,
1851). Today it is well accepted that the progressive loss of
functional muscle tissue and its replacement by adipose and
fibrous tissue represent a pathology common to all MDs despite
their heterogeneous genetic etiology. Most MDs are caused by
gene mutations that lead to absence or dysfunction of structurally
and/or functionally important molecules of the muscle fiber [1,2].
The sarcoplasmic spectrin-related protein dystrophin is thought to
structurally stabilize the muscle fiber sarcolemma by linking the
actin-based cytoskeleton to the extracellular matrix via interaction
with the dystroglycan (DG)-complex. Lack or vast reduction of
dystrophin causes severe Duchenne muscular dystrophy (DMD)
[3] in humans and myopathy in corresponding mouse models,
such as the mdx [4] or mdx-3Cv [5] mouse. Mutations in several
glycosyltransferase-encoding genes, such as the fukutin related
protein (FKRP)o rLARGE lead to defective glycosylation of the a-
subunit of DG. This molecular defect underlies the second most
common group of MDs, the so called ‘‘secondary dystroglycano-
pathies’’. Numerous other MD-related molecules are not known to
directly interact with the DG complex, such as dysferlin or
calpain-3. Defective expression of dysferlin, a ubiquitously
expressed 230-kDa transmembrane protein that has been shown
to be involved in resealing muscle fiber membranes, causes limb-
girdle muscular dystrophy type 2B (LGMD2B) or Miyoshi-
myopathy in humans [6,7]. An inbred mutation in the murine
dysferlin (Dysf) gene makes the SJL-mouse a naturally occurring
animal model for the human dysferlinopathies [8]. Mutations of
the CAPN3 gene encoding the muscle-specific calcium-activated
neutral protease calpain-3, a proteolytic switch in muscle
remodeling [9], cause LGMD2A, a MD with a wide clinical
spectrum [10]. Again, the corresponding animal model, the Capn3-
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dystrophy [11]. Given the diverse and obviously unrelated
functions of these proteins, whose absence or dysfunction causes
MDs, a common pathomechanism driving the complex events of
parallel muscle regeneration and degeneration and progressive
proliferation of fibrous and fatty tissue seen in all MDs is likely but
still remains elusive. In the light of the fact that nearly 25 years ago
the DMD gene was identified as the molecular basis for Duchenne
MD, the lack of causative therapies has dampened earlier
therapeutic promises based on the discovery of molecular defects
underlying several MDs and underscores the imperative need for a
comprehensive understanding of pathology involved in these rare
but lethal diseases.
When starting to study age-related phenotypes of murine MDs,
we have observed the frequent and spontaneous occurrence of
skeletal muscle-derived tumors in our colony of C57BL/10-mdx
mice, suggesting a tumor-suppressive role of dystrophin in mice.
Therefore we extended our studies to other dystrophin mutations,
mouse strains, and even to other MD-mouse models for the most
frequent MDs in humans, like dysferlin, calpain-3 and Large,
respectively. We show that all of these MD-mouse lines are prone
to develop mixed soft-tissue sarcomas containing tumor elements
displaying histological and molecular characteristics of rhabdo-
myo-, fibro-, and liposarcoma. These MD-associated tumors share
complex, non-random genomic alterations affecting well-known
tumor suppressor as well as oncogenes and these cancer signatures
are already detectable in dystrophic muscle tissue, independent of
the underlying mutation. Consequently, we show that genomic
instability and DNA damage are present also in muscle of human
MD patients. Collectively, these data strongly support an
unprecedented general link between muscular dystrophy and
cancer, driven by the accumulation of DNA damage, chromosome
copy number aberrations, and finally the origin of cell clones
harboring cancer-like mutations in dystrophic muscle tissue. We
propose that - similar to pre-neoplastic lesions - the dystrophic
muscle is characterized by genomic instability, which contributes
to a common hyperproliferative pathomechanism promoting the
degenerative process in human MDs and favoring age-related
tumorigenesis in the respective mouse models.
Results
Spontaneous occurrence of skeletal muscle-derived
tumors in various dystrophin-deficient mouse lines
During the last two decades we have observed the spontaneous
occurrence of soft tissue tumors arising from various skeletal limb
and trunk muscles in our dystrophin-deficient C57BL/10 mdx-
mouse [4] cohort. These tumors arose in aged mdx mice (mean
age-of-onset: ,540 d) with an incidence of almost 40%, whereas
we never observed the occurrence of such tumors in our C57BL/
10 wild-type mice. In our colony of another dystrophin-deficient
mouse line, mdx-3Cv, which lacks both the muscle 427 kDa and
non-muscle 71 kDa dystrophin isoforms due to a mutation at the
intron-exon 66 junction [5], we observed the spontaneous
occurrence of skeletal muscle-derived tumors indistinguishable
from those observed in C57BL/10-mdx mice. However, mdx-3Cv
developed skeletal muscle-tumors at a significant older age (,660
d) and a decreased incidence of only 5% as opposed to our mdx
colony. Because we could not figure out if these differences were
due to the different genetic backgrounds (mdx: C57BL/10, mdx-
3Cv: C57BL/6 x B6C3Fe) or due to the different dystrophin-
mutations, we generated two novel mdx inbred strains, i.e. BALB/
c-mdx, and C3H-mdx, respectively, and further studied mdx-mice
on mixed C57BL/6 x BALB/c and C57BL/10 x B6C3Fe
backgrounds. Indeed we observed the spontaneous occurrence of
skeletal muscle-tumors also in these mdx-mice, underlining a strain-
independent tumor-suppressor role of dystrophin. Mean ages-of-
onset, incidences and gender distributions of tumor-formation
were strongly strain-dependent, whereby the C57BL/10 back-
ground was most tumor-susceptible (Table 1). The spontaneous
occurrence of skeletal muscle-associated tumors in different
dystrophin-deficient mouse lines independent of the underlying
dystrophin gene mutation supported a candidate tumor suppressor
role of dystrophin.
Mice mutated in dysferlin, calpain-3, and Large are also
prone to develop skeletal muscle-derived sarcomas
In order to learn whether other MD-genes, which are not
directly related to dystrophin, might also suppress tumor
formation, we studied mice lacking dysferlin (Dysf
SJL mutation
[8]; Dysf
2/2), calpain-3 (Capn3
2/2; knockout [11]), or Large
(Large
myd mutation [12]; Large
2/2). In a colony of Dysf
2/2 mice
inbred onto C57BL/10 (n=151), we also observed high incidence
(23%; male-to-female ratio ,3:1) of age-related sarcomas (,640
d), which mainly arose from proximal hind limb muscles. Also for
Dysf
2/2 mice a strain-dependent effect with respect to mean age
of sarcoma-onset was detected, which was more than 100 days
later (,755 d) when the mutation was bred on a mixed C57BL/10
x B6C3Fe background, whereas the sarcoma incidence remained
unchanged (22%). Notably, dysferlin-deficiency on the mixed
C57BL/10 x B6C3Fe background resulted in a predominant
abdominal wall location of sarcomas (Figure 1A, Table 1).
Based on the spontaneous occurrence of skeletal muscle-tumors
in mice deficient for the so far molecularly unrelated genes
dystrophin and dysferlin, we hypothesized that MD-genes in more
general might act as tumor suppressors. To this end, we conducted
a life-span study with mice lacking calpain-3, the animal model for
LGMD2A in humans. Indeed, also Capn3
2/2 mice developed
skeletal muscle-derived sarcomas at an incidence of 5%. Finally,
Author Summary
All kinds of muscular dystrophies (MDs) are characterized
by progressive muscle wasting due to life-long prolifera-
tion of precursor cells of myo- (muscle), fibro- (connective
tissue), and lipogenic (fat) origin. Despite discovery of
many MD genes over the past 25 years, MDs still represent
debilitating, incurable diseases, which frequently lead to
premature death. Thus, it is imperative to gain novel
insights into the underlying MD pathomechanisms. Here,
we show that different mouse models for the most
common human MDs frequently develop skeletal muscu-
lature-associated tumors, presenting as complex sarcomas,
consisting of myo-, lipo-, and fibrogenic compartments.
Collectively, these tumors are characterized by profound
genomic instability such as DNA damage, recurring
mutations in cancer genes, and aberrant chromosome
copy numbers. We also demonstrate the presence of these
cancer-related aberrations in dystrophic muscles from MD
mice prior to formation of visible sarcomas. Moreover, we
discovered corresponding genomic lesions also in skeletal
muscles from human MD patients, as well as stem cells
cultured thereof, and show that genomic instability
precedes muscle degeneration in MDs. We thus propose
that cancer-like genomic instability represents a novel,
unifying pathomechanism underlying the entire group of
genetically distinct MDs, which will hopefully open new
therapeutic avenues.
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myd mice (representing a model for a severe congenital MD in
humans), in spite of their considerably short lifespan (Table 1).
Combined defects in MD genes accelerate
sarcomagenesis in mice
In order to test if dystrophin, dysferlin and calpain-3 have
tumor-suppressor effects in vivo, we generated double-mutant
mouse lines, i.e. dystrophin-deficient (mdx) mice with additional
lack of either dysferlin (Dmd
2/2 Dysf
2/2) or calpain-3 (Dmd
2/2
Capn3
2/2). Dmd
2/2 Dysf
2/2 mice (C57BL/10) clinically
presented with significant weakness characterized by severe
dystrophic signs in the skeletal muscle (R.B., manuscript in
preparation), and had a severely reduced life-span of ,13 months.
Remarkably, malignant skeletal muscle-derived sarcomas
(Figure 1B) constituted the main cause of premature death in this
condition. While penetrance was sharply increased in male mice,
63% of which developed sarcomas, a dramatic decrease in tumor
latency was observed in both genders, with the mean age-of-onset
reduced to ,390 d (compared to 540 d in Dmd
2/2 and 640 d in
Dysf
2/2).
The combined effect of Dmd
2/2 Capn3
2/2 in double-knockout
mice, which also presented with a severe MD-phenotype leading
to a shortened life-span of ,13 months (R.B., manuscript in
preparation), resulted in spontaneous sarcoma-formation in 44% of
the animals with a mean-age of onset of ,390 days (Figure 1C).
Thus, additional loss of both dysferlin and calpain-3 in dystrophin-
deficient mdx mice dramatically reduced sarcoma latency
(Figure 1D).
The skeletal muscle-derived tumors in MD mice present
as mixed rhabdo-, fibro-, and liposarcomas
Because the macroscopic appearances of the skeletal muscle-
derived tumors showed areas of different colorings and varying
consistencies (Figure 1E), we speculated that this might be due to a
mixed composition of diversely differentiated tumor-cell lineages.
Indeed, careful histopathological examinations revealed that all
tumors independent from the underlying MD mutation(s)
resembled mixed sarcomas, comprising variably sized coexisting
compartments of rhabdomyosarcoma (RMS), fibrosarcoma (FS)
and liposarcoma (LS), respectively (Figure 1F–1K). Histopathology
of RMS mainly presented as embryonic (ERMS) or spindle-cell
tumors, which expressed myogenic factors to various degrees, such
as myogenin (Figure 1G), Myf5, or desmin (not shown). Also at the
ultrastructural level, these tumor compartments were composed of
cells with myofibrils, which were partly arranged in sarcomeric
manner (Figure 1L). Tumor-compartments identified as FS
displayed bundles of collagen fibres and immature, proliferating
Table 1. Incidence and age-of-onset of malignant sarcomas in MD mouse models.
Genotype
Strain
background Cohort Sarcomas Incidence
a Mean age [CI (95%)]
Female/male
ratio
Tumor site
predilection
Dystrophin
Dmd
2/2 (mdx) C57BL/10 n=122 48 39% 539 d [516–562] 1: 1.1 proximal hind limb,
trunk, head & neck
C57BL/106B6C3Fe
b n=46 8 17% 580 d [460–700] 1.7: 1 proximal hind limb,
trunk, head & neck
C57BL/66BALB/c
c n=99 10 10% 651 d [567–735] 1: 1.4 proximal hind limb,
fore limb, head & neck
BALB/c n=82 7 9% 515 d [413–607] 1: 1.3 proximal hind limb,
head & neck
C3H n=60 9 15% 523 d [411–635] 2.5: 1 proximal hind limb,
trunk, head & neck
Dmd
2/2(mdx-3Cv) C57BL/66B6C3Fe
d n=55 3 5% 663 d n.a. n.a. n.a.
Dysferlin
Dysf
2/2 C57BL/10 n=151 35 23% 640 d [601–679] 1: 2.9 proximal hind limb and
trunk
C57BL/106B6C3Fe
b n=78 17 22% 755 d [686–804] 1: 2.9 trunk
Large
Large
2/2 (myd) B6C3Fe
c n=71 1 1% 278 d n.a. n.a. n.a.
Calpain
Capn3
2/2 C57BL/66[129/Sv:
C57BL/6]
d
n=19 1 5% 716 d n.a. n.a. n.a.
Dystrophin-Dysferlin
Dmd
2/2 Dysf
2/2 C57BL/10 n=89 42 47% 389 d [369–409] 1: 2.4 proximal hind limb,
fore limb, trunk, head &
neck
Dystrophin-Calpain
Dmd
2/2 Capn3
2/2 C57BL/106[129/Sv:
C57BL/6]
b
n=55 24 44% 391 d [360–422] 1: 1.6 proximal hind limb,
trunk
a Incidences of clinically overt sarcomas. Different C57BL/6 proportions in mixed backgrounds are indicated: b 25%, c 50%, and d 75% C57BL/6.
n.a.: not applicable.
doi:10.1371/journal.pgen.1002042.t001
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hereby recapitulating the histopathological hallmark of human FS
(Figure 1F, 1I). The third identifiable compartment was LS
consisting of lipocytes, which showed both well-differentiated and
de-differentiated morphologies. The unifying characteristics of all
LS-cells were positivity for lipid staining by Sudan Black
(Figure 1H) and, moreover, immunoreactivity for Cdk4 (a human
LS biomarker) (Figure 1K). By electron microscopy, LS-cells
characteristically contained numerous fat droplets (Figure 1M). In
line with the histological findings, propagated tumor cell cultures
also revealed co-existence of different cell types (Figure 1N), most
prominently myogenin-positive cells and lipogenic but myogenin-
negative cells (Figure 1O), providing further support that tumors
arising in MD-mice are mixed-type sarcomas. Because these
findings disclosed all MD-tumors as complex, mixed sarcomas, we
next studied the expression of select human sarcoma-related genes
[13]. Indeed we found increased expression levels for RMS-
markers (Myog, Myl4, Igf2, Prox1), a FS-gene (Vcan), and LS-related
genes (Pparg, Myo1e, Hoxa5, Plau), which further established the
MD-tumors as mixed sarcomas consisting of RMS, FS and LS-
compartments (Figure S1).
Genomic hallmarks of murine MD sarcomas:
amplification of Met and Jun, loss of Cdkn2a and Nf1, and
whole chromosome 8 and 15 gains
In order to characterize the emerging link between MD and
sarcoma susceptibility, we investigated genetic lesions in tumors
originating in our MD-mouse strains. DNA extracted from solid
tumors from Dmd
2/2 or Dysf
2/2 mice was subjected to an
arrayCGH-based screen (n=8), which revealed that the majority
of Dmd
2/2 tumors were characterized by multiple segmental
chromosomal changes, chromosome number aberrations, and
amplification of loci harboring the Met (encoding the Met proto
oncogene hepatocyte growth factor receptor) or Jun oncogene,
while tumors from Dysf
2/2 mice typically displayed less genomic
instability (Figure 2A). Frequent disruption of the tumor
suppressor loci Cdkn2a, encoding p16
INK4a and p19
ARF, Nf1,
encoding neurofibromin 1, and Trp53, together with whole
chromosome 8 and/or 15 gains represented key non-random
alterations of sarcomas in both MD models.
Quantitative PCR (qPCR) experiments (Figure 2B and 2C) of
DNA extracted from tumors of Dmd
2/2, Dysf
2/2, Dmd
2/2
Dysf
2/2, and Dmd
2/2 Capn3
2/2 mice (n=98) revealed that
these genetic lesions were common but occurred at different
degrees, depending on the specific gene defect(s). Frequent
amplification of Met or Jun oncogenes was observed in Dmd
2/2
(41%) and Dmd
2/2 Dysf sarcomas (44%). In contrast, amplifica-
tions of Mdm2 and/or Cdk4 (which were additionally tested
because of their frequent amplification in human sarcomas, most
prominently liposarcomas [14]) were rare (,5%; not shown).
Lesions of the Nf1 gene (exons 23 and/or 56) were more
frequently found in Dmd
2/2 (34%) and Dmd
2/2 Dysf
2/2
sarcomas (31%) as opposed to Dysf
2/2 (14%) or Dmd
2/2
Capn3
2/2 (18%). Conversely, exon 2 of the Cdkn2a tumor
suppressor gene, which encodes parts of both p16
INK4a and
p19
ARF, was reduced in 73% of Dysf
2/2 tumors whereas ,50%
of Dmd
2/2 Dysf
2/2 and Dmd
2/2 Capn3
2/2 tumors carried this
deletion. Notably, many of the qPCR-ratios obtained for Cdkn2a
and Nf1 were consistent with losses throughout the tumor. In 25%
of DNA samples from sarcomas with qPCR values indicating
Cdkn2a loss, exon 2 copy numbers were ,0.2, which suggested the
presence of a homozygous deletion in ,80% of tumor cells,
compatible with an early event in tumorigenesis.
Based on the arrayCGH-findings we screened a large cohort of
tumors also for chromosome 8 and 15 copy number aberrations.
We found gains of either or both chromosomes in the vast majority
(80%) of sarcomas. While ,40–60% of tumors from all MD
models displayed gains of both chromosomes, chromosome 8
alone was preferably gained in Dysf
2/2 and chromosome 15 in
Dmd
2/2 tumors indicating a probable MD-specific preference
(Figure 2C).
Sarcoma and dystrophic muscle display similar patterns
of genomic instability
More than 50% of the measured chromosome 8/15 ratios were
consistent with gains throughout the tumor, implying the presence
of trisomies in more than 90% of tumor cells. This suggested that
together with losses at Cdkn2a and Nf1 loci the recurrent
duplications of these chromosomes belong to early events in
sarcoma development. Thus, we argued that such events might
occur in skeletal muscles of MD-mice prior to formation of
clinically identifiable tumors.
To test this hypothesis, we assessed chromosome 8 and
chromosome 15 copy numbers in DNA samples extracted from
a panel of typically tumor-prone limb muscles (n=101), which
were obtained from different animals (n=31) that were sacrificed
at advanced ages (comparable to the mean age of mice with
sarcomas in the respective MD models) but had not developed
visible tumors until then (Figure 3A). We found elevated levels of
chromosome 8 and/or 15 in ,30% of muscles from MD-mice but
Figure 1. MD mice are prone to develop skeletal muscle-related malignant mixed mesenchymal tumors. (A) Dysferlin-deficient mouse
(male, 878 d) with sarcoma located in the caudal abdominal wall (arrow; weight of excised tumor: 4.2 g). (B) Dystrophin-dysferlin double-mutant
(male, 250 d) with very large sarcoma (9.1 g), which arose in proximal and distal skeletal muscles of the left hindlimb (arrow). (C) Dystrophin-calpain3
double-mutant (male, 474 d) with sarcoma (2.3 g) located in ischiocrural muscles of the right hindlimb (arrow). (D) Graphical representation of
sarcoma incidence and age-of-onset from life-span studies of mice lacking dystrophin (n=48/122; C57BL/10), dysferlin (n=35/151; C57BL/10), or
calpain 3 (n=1/19; 129/Sv x C57BL/6) and of dystrophin-dysferlin (n=42/89) and dystrophin-calpain 3 (n=24/55) double-mutant mice. Error bars
indicate confidence interval of the mean (95%). (E) Representative examples of excised tumors (from dystrophin-dysferlin double-mutant mice) with
myo- (*), lipo- (u), and fibrosarcomatous (ˆ
) compartments macroscopically recognizable as different parts of the tumor mass. (F–H) Histological
examination of the tumor shown in E (upper panel) revealed a sarcoma with mixed mesenchymal differentiation characterized by rhabdomyo- (*),
lipo-(u), and fibrosarcoma (ˆ
) components. Serial sections used for H&E staining (F), myogenin staining (G), and double staining with myogenin and
Sudan Black (H). (I) Morphological analysis of a sarcoma that arose in a 486 d-old C57BL/10 mdx mouse revealing a prominent fibrosarcoma areal
characterized by the typical collagen fibres bundles arranged in ‘‘herringbone pattern’’ (H&E). (J,K) Well-differentiated liposarcoma area within a
mixed sarcoma from a Dmd
2/2 Capn3
2/2 double-mutant mouse (J, H&E), with intense Cdk4-positivity (K). (L) Electron micrograph showing a
rhabdomyosarcoma cell displaying myofibril structures. (M) Electron micrograph from the same tumor showing a liposarcoma cell densely packed
with large lipid vesicles and exhibiting a highly aberrantly shaped nucleus. (N) Photomicrograph showing cultured tumor cells propagated from a
typical mixed sarcoma (from a dysferlin-deficient mouse), indicating the presence of different types of tumor cells (round-shaped, spindle cell-like,
and myotube-like elongated rhabdomyoblasts). (O) Photograph of two tumor cells grown in vitro from the same explanted tumor. Double-staining
for myogenin and Sudan Black depicted a myogenin-positive myogenic tumor cell next to a myogenin-negative but lipogenic tumor cell containing
Sudan Black-positive droplets.
doi:10.1371/journal.pgen.1002042.g001
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PLoS Genetics | www.plosgenetics.org 5 April 2011 | Volume 7 | Issue 4 | e1002042Figure 2. Common non-random genetic lesions in MD-mouse sarcomas. (A) Chromosomal aberration profiles from Agilent aCGH
experiments performed on tumor DNA isolated from sarcomas of n=4 Dmd
2/2 (black) and n=4 Dysf
2/2 (grey) mice revealing gross genomic
instability, specific losses at the Cdkn2a, Nf1, and Trp53 tumor suppressor loci, amplification of Met and Jun oncogenes, and recurrent gains of whole
chromosome 8 and 15. (B) Real-time PCR quantification of Met and Jun oncogene amplification, losses at the Cdkn2a and Nf1 loci, and of
chromosome 8 and 15 copy numbers in n=98 sarcomas from Dmd
2/2 (X), Dysf
2/2 (J), Dmd
2/2 Dysf
2/2 (XJ), and Dmd
2/2 Capn3
2/2 (CX) mice.
Relative copy numbers (shown as log2) were calculated by the DDCt-method. Dashed lines indicate log2-thresholds that were set under the
assumption of 80% tumor cell content: gene amplification (4-fold; Met and Jun), deletions (first line for heterozygous losses, 0.5-fold, second line for
homozygous losses; Cdkn2a and Nf1), and chromosome copy numbers (3 and 4). (C) Frequency plots for Met and Jun amplification, Cdkn2a and Nf1
deletions, and chromosome 8/15 gains from the n=98 sarcomas shown in (B).
doi:10.1371/journal.pgen.1002042.g002
Genomic Instability in Muscular Dystrophies
PLoS Genetics | www.plosgenetics.org 6 April 2011 | Volume 7 | Issue 4 | e1002042Genomic Instability in Muscular Dystrophies
PLoS Genetics | www.plosgenetics.org 7 April 2011 | Volume 7 | Issue 4 | e1002042never in wild-type mice (Figure 3B). Also occasional copy number
aberrations of the Cdkn2a, Nf1, Met and Jun genes were detected in
dystrophic muscles (,12%). Because the extents of some of these
findings were clearly compatible with the presence of malignant
cell clones within the tested muscles, we next analyzed these
muscles microscopically. Indeed we found variably sized micro-
scopic tumor masses residing between muscle groups and within
single muscle fascicles (Figure 3C). Immunohistochemical exam-
ination of these tumors in situ revealed intense staining of cell
proliferation markers (p27, PCNA) as well as Cdk4 (Figure 3D),
compatible with high proliferative activity.
These findings clearly showed (i) that tumor pre-stages and pre-
neoplastic lesions are already present in dystrophic muscle and (ii)
that the actual sarcoma incidence of MD-mice is much higher
than that solely based on the occurrence of visible tumors. Because
none of these DNA-abnormalities were present in non-muscle
tissues (i.e. brain, liver, and lung) we concluded that these somatic
aberrations are specific to dystrophic skeletal muscle.
Recurrent patterns of somatic aneuploidy in various
types of human muscular dystrophies
To address whether aneuploidy affects also human MD, we
analyzed primary myoblast lines from DMD and LGMD2B
patients. In myoblast DNA samples from a DMD and a LGMD2B
patient as well, arrayCGH revealed profiles indicating borderline
gains of several chromosomes. In particular, aberration scores
indicated gains of chromosome 19 (Figure 4A). To confirm this
finding, interphase fluorescent in situ hybridization (I-FISH)
experiments were performed on cytospin preparations from
early-passage myoblast cell cultures of DMD (n=4), and
LGMD2B (n=3) patients, as well as healthy donors (n=2). In
contrast to normal cells, myoblasts from DMD and LGMD2B
patients frequently harbored tetrasomies of chromosome 19 (13–
27%; Figure 4B). Additional analyses for other chromosomes
revealed multiple aneusomies, such as tri- and tetrasomies of
chromosomes 1 (5–8%), 2 (3–6%), and 8 (4–20%; Figure 4C). In a
DMD myoblast cell line, metaphase spreads displayed formation
of diplochromosomes (i.e. pairs of sister chromosomes, generated
by endoreduplication) (Figure 4D), which are indicative for
heterogeneous chromosomal instability and aneusomies. DNA
content analyses by FACS profiling of propidium iodide-stained
cells revealed that myoblasts from DMD and LGMD2B patients
contained abnormally high proportions of nuclei with aberrant
DNA-content, indicated by prominent G0+ peaks (Figure 4E).
Targeted FISH analysis of nuclei isolated through sorting of such
G0+ peaks verified the presence of genomes harboring chromo-
some 8 aneusomies (Figure 4E, insets). Moreover, the occasional
presence of micronuclei implied the continual induction of
numerical or structural chromosomal damage in MD-myoblast
lines.
In order to preclude that the observed chromosomal copy
number aberrations had been acquired or at least amplified in vitro,
as reported for embryonic stem cells [15] and committed
progenitor cells [16], we asked whether aneusomies also represent
an in vivo genotype and do exist in skeletal muscle tissue of MD
patients. To this end, interphase nuclei from frozen muscle
biopsies from human MD-patients were isolated and probed by I-
FISH. We detected tri- and/or tetrasomies of chromosomes 2
and/or 19 in ,5–12% of the nuclei isolated from DMD muscle
(n=4) (Figure 4F). In contrast, counts of chromosome 13, for
which normal copy numbers were found in myoblasts, were
readily comparable to control muscles (Table 2). Similarly,
aberrant chromosome 2 and 19 counts were detectable in muscle
biopsies from patients with LGMD2A (n=3, CAPN3 mutations),
LGMD2I (n=3, FKRP mutations), as well as LGMD2B (n=1,
DYSF mutations) (Figure 4G). Notably, LGMD2A muscles
exhibited slightly aberrant counts also for chromosome 13 (4.6%
versus 1% in controls). Generally, poly-/aneusomic nuclei further
displayed features like enlargement, more irregular shape, and
micronucleus formation, when compared to disomic nuclei. I-
FISH signals in nuclei with aneusomic configurations frequently
appeared either as highly condensed doublet signals (in particular
for chromosome 19) or as bizarre structures with highly elongated
conformation, indicating increased variability of differential
(probably abnormal) states of chromatin condensation (Figure 4F,
4G). In order to learn if the degree of aneusomies correlates with
the disease progression of muscular dystrophies, we also studied
fetal muscle obtained during autopsy of aborted fetuses with
prenatal diagnosis of DMD or MDC1C. Indeed, these fetal muscle
tissues contained much less chromosomal copy number aberra-
tions (chr2: ,1% versus 0.2% in controls; chr13: 0.6% versus 0%;
chr19: ,3% versus 1%). Thus, compared to age-matched control
muscles, we observed an age-dependent increase of the frequency
of aneusomic nuclei in MD patients (Figure 4H, 4I).
Widespread activation of the DNA damage response in
muscular dystrophies
The finding of cancer-like mutations and somatic aneuploidy in
dystrophic muscle prompted us to speculate that this might be
caused by damage to DNA induced e.g. by oxidative or replication
stress. The formation of interstitial deletions and intrachromo-
somal amplifications, which we found in pre-neoplastic lesions and
sarcomas arising in murine MDs, belong to typical genetic
aberrations that result from unrepaired DNA double-strand
breaks (DSB) [17] and represent early events in the development
of cancer [18]. To explore whether damage to genomic DNA
precedes sarcoma development, we studied the canonical DNA
damage response pathways in skeletal muscle from dystrophic
mice. When analyzing muscle tissue from Dmd
2/2 mice,
pronounced activation of the two major DNA damage response
Figure 3. Genetic alterations frequently found in sarcomas are detectable in dystrophic skeletal muscle from clinically tumor-free
mice. (A) Heatmap representation of real-time PCR results from quantification of Jun, Met, Cdkn2a, Nf1 (exon 23 and 56, respectively), and
chromosome 8 and 15 copy number in DNA samples extracted from tumor-prone skeletal muscles (QF: quadriceps femoris, TA: tibialis anterior, TRIC:
triceps brachii, TS: triceps surae, ISCH: ischiocrural muscles, ILP: iliopsoas, GAC: gastrocnemius, SOL: soleus) from n=20 different aged MD-mice (mean
age of mice: Dmd
2/2: 590 d; Dysf
2/2: 640 d; Dmd
2/2 Dysf
2/2: 482 d) without clinically overt tumors (boxes indicate different individuals). qPCR
measurements were highly suggestive of occasional copy number aberrations of the Cdkn2a, Nf1, Met and Jun genes, and chromosome 8 and 15 as
well. Muscles from dysferlin-deficient mice that were selected for histopathological examination shown in (C) and (D) are indicated. (B) Real-time PCR
results (shown as -DCt values) for chromosome 8 and 15, and Cdkn2a revealing elevated levels of chromosome 8 and/or 15 in ,30% and losses at the
Cdkn2a locus in some of muscles from MD-mice but never in wild-type (WT) mice. Some of the observed values indicated relatively high fractions of
cells harboring the respective alterations (indicated by filled red circles). (C) Histological examination of 3 select muscles from the genetic screen
shown in (A) revealed presence of variably sized microscopic tumor masses, suggestive of well-differentiated liposarcoma, residing between muscle
groups and within single muscle fascicles. (D) Histological and immunohistochemical examination of a TA-muscle sample from a 594 d-old Dysf
2/2
mouse, revealing the presence of tumor cells characterized by positive staining for Cdk4 and p27.
doi:10.1371/journal.pgen.1002042.g003
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Ser1981-posphorylated ATM (p-ATM, ataxia-telangiectasia mu-
tated kinase) and Ser428-posphorylated ATR (p-ATR, ATM and
Rad3-related), and of their downstream signaling targets Chk1 and
Chk2 (not shown). We next investigated histone H2A.x, which
represents a target of the ATM pathway that signals the presence
of DSBs and constitutes a key protein of the DNA damage
response by accumulating at large stretches of chromatin
surrounding DSBs and recruiting repair factors [19]. In contrast
to normal controls, muscle from MD mice was characterized by
intense immunoreactivity with an antibody specifically detecting
Ser139-phosphorylated histone H2A.x (c-H2A.x), similar to the
reactivity observed in sarcomas (Figure 5A–5C).
We then examined the DNA damage response in muscle
biopsies obtained from human DMD patients. In contrast to
healthy control muscles, c-H2A.x immunostainings revealed high
levels of DSBs in muscle biopsies from all DMD patients (n=4)
tested, with multiple nucleoplasmic foci formation belonging to
Table 2. Somatic aneuploidy in human skeletal muscle from MD patients.
disomies (%) aneusomies (%)
Group Sample ID Age (a) chr2 chr13 chr19 chr2 chr13 chr19
Controls
Control-fetal FK prenatal 88 91 85 0.0 0.0 1.0
Control-fetal FP prenatal 91 94 88 0.5 0.0 1.4
Control M2232 2 87 81 79 0.7 1.0 1.3
Control M1856 3 87 67 81 0.8 2.1 1.1
Control M2066 4 91 93 84 1.1 0.0 0.7
Control -adult M826 44 93 87 79 0.5 0.5 0.5
Control -adult M1006 49 87 79 70 1.1 1.4 0.0
Control -adult M983 52 87 91 70 2.3 0.0 1.1
Control -adult M689 52 84 74 77 1.1 1.6 1.7
DMD
DMD-fetal FL prenatal 85 93 86 2.2 0.6 4.9
DMD-fetal FB prenatal 83 92 81 0.0 0.5 1.4
DMD M2006 1 82 88 84 2.7 0.0 3.3
DMD M1994 7 71 82 70 8.3 2.4 6.8
DMD M1895 8 76 86 66 5.9 3.6 8.8
DMD M1959 15 58 75 54 11.2 2.0 6.1
DYSF
LGMD2B-adult M2057 62 58 n.a. 46 17.7 n.a. 7.5
FKRP
MDC1C-fetal M2166 prenatal 88 89 83 1.7 0.5 2.6
LGMD2I M1787 10 69 81 55 7.3 1.9 6.1
LGMD2I -adult M2190 28 62 80 62 7.1 0.7 3.3
CAPN3
LGMD2A M1883 9 77 84 66 3.9 4.1 4.6
LGMD2A M2207 13 79 87 77 6.1 6.0 4.6
LGMD2A-adult M2219 25 73 84 70 3.8 3.5 2.8
n.a.: not analyzed
doi:10.1371/journal.pgen.1002042.t002
Figure 4. Somatic aneuploidy in human muscular dystrophies. (A) Agilent aCGH profile (50 Mbps moving average) of cultured human
myoblasts from a female LGMD2B patient (‘‘90/01’’). Mean-fold changes (compared to pooled DNA from n=6 healthy male controls) were highly
suggestive for gains of several chromosomes, especially for chromosome 19 (arrow). (B,C) I-FISH on myoblasts verified the presence of nuclei with
aberrant chromosome 19 (tetrasomy shown in B) and chromosome 8 counts (trisomy shown C). (D) Diplochromosome formations (arrows) in a
metaphase spread prepared from DMD myoblasts. (E) DNA content analyses by FACS profiling of propidium iodide (PI)-stained myoblasts from DMD
and LGMD2B patients revealed abnormally high proportions of nuclei with aberrant chromatin content indicated by highly prominent G0+ peaks
compared to the control myoblast line. Insets show targeted FISH analyses of nuclei isolated through sorting G0+ peaks, which verified the presence
of chromosome 8 trisomies (green: 8cen, red: 18cen). (F,G) Interphase FISH on nuclei isolated from cryofixed skeletal muscle tissue from DMD patients
(F) and LGMD2A, LGMD2B and LGMD2I patients (G), probed with chromosome 2p (red) and chromosome 19q (green) probes. Close-up in one
LGMD2B example depicts micronucleus formation. (H) Frequency histogram of chromosome 2p and 19q aneusomies (gains, black, and losses, dark
grey) compared to the normal disomic configuration (light grey) in prenatal, young, and adult patients with MD and healthy controls. (I) Age-
dependent decline of normal disomic configuration (chromosome 2p and 19q) and increase of aneusomies in skeletal muscle from MD patients (red,
as indicated) in contrast to controls (blue). Outlined symbols correspond to aneusomies. Dashed lines indicate linear trends.
doi:10.1371/journal.pgen.1002042.g004
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endomysial connective tissue, such as interstitial fibroblasts and
endothelial cells (Figure 5D, 5E). We further found that DNA-
damage response was already present in pre-pathologic muscle
from very young patients (9–11 months) and a DMD fetus,
which suggested that DNA-double strand breaks very likely
occur prior to clinical onset of muscle weakness, wasting, and the
concomitant inflammatory response. Also muscle tissue in
samples from LGMD2A (CAPN3, n=3), LGMD2I (FKRP,
n=2), MDC1C (FKRP), and LGMD2B patients (DYSF) exhibited
intense c-H2A.x immunoreactivity and multiple nucleoplasmic
foci formation (not shown). That both muscle-fiber nuclei and
non-muscle cell nuclei displayed massive c-H2A.x accumulation
prompted us to specifically assess the DSB response in myogenic
precursor cells. We investigated primary muscle cell cultures
generated from DMD and LGMD2B patients. In contrast to
myoblasts from healthy donors, nuclei from DMD and
LGMD2B myoblasts showed pronounced accumulation of c-
H2A.x foci (Figure 5F–5I). The formation of distinct nuclear
immunofluorescent foci was observed in 49% of cells from DMD
and 59% from LGMD2B myoblasts (compared to 24% in
controls) and the number of cells with multiple ($3) foci was also
Figure 5. Pronounced DNA damage response in murine and human dystrophic muscle. (A–C) Intense immunoreactivity with an antibody
detecting Ser139-phosphorlated histone H2A.x (c-H2A.x) in skeletal muscle from a dystrophin-deficient (mdx) mouse (B) and in a sarcoma from a mdx
mouse as well (C), in contrast to wild-type (WT) muscle (A). (D–E) In contrast to a healthy control (D), c-H2A.x immunostainings revealed high levels of
DSBs in muscle biopsies from DMD patients (E), with multiple nucleoplasmic c-H2A.x foci formation in nuclei belonging both to muscle fibres (arrows)
and non-muscle cells (arrow-heads). Close-up panel (E’) shows two nuclei with intense foci formation. (F–H) Pronounced accumulation of c-H2A.x foci
in cultured myoblasts from LGMD2B patients (G, ‘‘362/03’’ and H, ‘‘90/01’’), in contrast to myoblasts from a healthy donor (F, ‘‘363/07’’).
(I) Quantification of c-H2A.x immunoreactivity revealed increased total reactivity and a prominent increase of cells with multiple ($3) foci (log10 =
0.5) in myoblasts from LGMD2B (‘‘362/03’’) and DMD (‘‘88/07’’) patients compared to a control myoblast line (‘‘363/07’’). Fluorescence intensity is
shown in a log2 scale, foci number is log10.
doi:10.1371/journal.pgen.1002042.g005
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10%).
Discussion
MD mice are prone to develop age-related mixed
rhabdo-fibro-liposarcomas
Here we show that different types of MD mouse models develop
with increasing age mixed soft-tissue sarcomas (STS), presenting as
rhabdo-fibro-liposarcomas. While the spontaneous occurrence of
RMS has been previously reported in mdx mice [20] and in
addition in mice deficient of a-sarcoglycan [21] (Sgca
2/2, a model
for the human LGMD2D), this is the first report of sarcomas in
mice lacking dysferlin, calpain 3, or Large. Our work further
shows for the first time that also mice lacking dystrophin due to
other mutations than mdx and on different genetic backgrounds are
prone to develop age-related STS. In contrast to the previous
reports, we found that virtually all sarcomas from MD mice
histologically present as mixed sarcomas consisting of RMS and of
two additional components with fibro- and liposarcomatous
differentiation. Macroscopically, sarcomas feature considerable
heterogeneity regarding visual appearance and consistency of
tumor mass. Similar to the high complexity and histological
diversity inherent to human sarcomas, we found it extremely
difficult to exactly stage individual tumors due the highly complex
and heterogeneous structure and significant sectional plane
divergence. Therefore, our finding of mixed sarcomas in mdx
and other MD mice rather extends than rebuts the previous
reports by Chamberlain et al. [20], who reported alveolar RMS in
mdx, and Fernandez et al. [21], who described embryonal RMS in
mdx and also Sgca
2/2mice. As a further difference, sarcoma
incidence in our C57BL/10 mdx mice (39%) was clearly higher
compared to the previously reported RMS incidences (,6–9%). It
remains elusive if these differences are due to different housing
conditions or other unknown environmental or strain-specific
factors.
It is, however, remarkable that the three main components of
malignant cell-types, i.e. myo-, fibro-, and lipocytes, which we
observed in our MD-mouse tumors, correspond exactly to the
same cell- and tissue types that are crucially characterized by
progressive proliferation in MDs. Thus, the MD-associated
proliferation of fat and connective tissue might create the
molecular context permitting sarcoma development arising from
a multipotent mesenchymal or muscle-derived stem cell.
MD-genes display some features similar to tumor
suppressors
Several observations in our study lend support to the speculative
view that MD-genes might have a role as tumor suppressors. We
found that strain backgrounds with C57BL/6 proportions
obviously exerted protective effects with regard to tumor latency
and that tumor penetrance was lower in Dmd
2/2 mice on C3H or
BALB/c backgrounds compared to C57BL/10. In line with our
observation, C57BL/6 is known for its resistance to Ptch1
+/2-
induced rhabdomyosarcomas [22]. Genetic background also
clearly influenced tumor gender specificity in Dmd
– mice (male
preference in BALB/c, female in C3H) and tumor site predilection
in Dysf
2/2 mice (,60% abdominal wall tumors in C57BL/10 x
B6C3Fe compared to ,20% in C57BL/10). Such strain-specific
modulation of incidence, latency, location spectrum, and gender
preference has been well documented for other cancer models,
such as the p53-deficient mouse [23]. The significantly reduced
sarcoma latency in double-mutant Dmd
2/2Dysf
2/2- and Dmd
2/2
Capn3
2/2 mice also resembles a common feature of tumor
suppressor mouse models, as exemplified by the synergistic effect
of a combined loss of p53 and Nf1, which accelerates soft-tissue
sarcoma development [24]. Thus, the effects we observed for MD-
gene losses represent classical credentials of tumor suppressor
genes. In support of this view, dystrophin has been linked to
human cancer, as its frequent inactivation was shown to be
involved in the pathogenesis of malignant melanoma [25].
Notably, in melanoma cell lines dystrophin knock-down enhanced
migration and invasion, whereas re-expression attenuated migra-
tion and induced a senescent phenotype, fully in line with a tumor
suppressor role of dystrophin [25]. Moreover, utrophin, the highly
related autosomal paralogue of dystrophin, represents a tumor
suppressor candidate, owing to its frequent disruption in human
malignant tumors and its capability to inhibit breast cancer cell
growth [26]. Notably, aberrations of the DG have been associated
with several types of human cancer [27–30], suggesting a potential
role also in tumorigenesis. In particular, a tumor suppressor
function has been suggested for laminin-binding glycans on a-
dystroglycan [31], whose loss can be caused by silencing of the
LARGE gene in several metastatic epithelial cell lines [30]. For
both, dystrophin [32] and dysferlin [33] interactions with the
microtubule network have been recently described, which suggests
their hypothetical implication in microtubule-mediated cell
functions, such as mitosis and cell migration. Future studies will
be needed to clarify whether MD-genes act as tumor suppressors,
which is suggested but not proven by our data.
Recurrent non-random genetic lesions in MD sarcomas
We found that murine sarcomas from MD-mice frequently
harbor non-random, recurrent genetic lesions that provide links to
human mesenchymal cancers. The pivotal p53 and retinoblastoma
(RB) cell cycle control pathways were frequently incapacitated by
the disruption of the Cdkn2a locus, which encodes two different
tumor suppressors, the Cdk4 kinase inhibitor p16
INK4a and the
Mdm2-p53 regulator p19
ARF, both of which play an important
role in the development and progression of many human cancer
types. Deletions at Trp53 and Nf1 loci established a genetic link to
human soft-tissue sarcomas, which are characterized by frequent
p53 mutations [34–36], as well as to syndromes associated with
increased RMS incidence due to germ-line disruption of these
tumor suppressor genes (Li-Fraumeni, TP53; Neurofibromatosis
type I, NF1) [37]. More recently, human myxofibrosarcoma and
pleomorphic liposarcomas were shown to frequently harbor NF1
mutations [14]. Thus, the disruption of Nf1 in sarcomas from MD-
mice parallels specific - non myogenic - subtypes of human soft-
tissue sarcomas and suggests a more general role for Nf1-lesions in
the genesis of mesenchymal cancers. A high fraction of sarcomas
from MD-mice harbored amplifications of the Met or Jun
oncogenes. The Met oncogene amplification constitutes a critical
path to aberrant activation of the Hgf/c-Met axis, which is known
to promote tumorigenesis and to be involved in the progression
and spread of multiple human cancers. Amplification of the JUN
oncogene has been reported in human liposarcomas [38–39], in
sound accordance with herein discovered frequent Jun amplifica-
tion in MD mixed sarcomas.
Our finding of recurrent chromosome 8 and/or 15 gains in MD
sarcomas provides a link to other murine cancers. Chromosomes 8
and/or 15 are frequently duplicated in T cell tumors [40–41] or
transgenic mouse models of acute promyelocytic leukemia [42],
and probably contribute to elevated expression of the Junb and/or
Myc oncogenes, as suggested for Myc in T cell lymphomas [41].
Notably, several human malignancies, amongst them myxoid/
round cell liposarcoma [14], are known to harbor recurrent gains
of chromosome 8. Most importantly, the human chromosome 8
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chromosomes 8 and 15, which we found to be regularly gained
in the MD-sarcomas.
Dystrophic skeletal muscle from mice and humans
harbors cancer signature, somatic aneuploidy, and DNA
damage
We discovered that the most frequent and most prominent genetic
alterations that characterize full-blown skeletal muscle-derived
sarcomas are already present in dystrophic skeletal muscle of
clinically tumor-free mice. We also demonstrated DNA damage
and showed that skeletal muscle of MD-mice harbors microscopic
tumor infiltrates prior to the development of macroscopically visible
tumors. In particular, our findings suggested that somatic aneuploidy,
indicated by recurrent gains of chromosomes 8 and 15, contributes to
sarcoma susceptibility in murine MD. Thus, the frequent occurrence
of chromosome 8/15 gains together with specific losses at the Cdkn2a
locus might represent early events occurring in cancer pre-stages and
promoting malignant transformation [43]. Importantly, these
findings also suggested that the actual sarcoma incidence of MD-
mice is much higher than that solely based on the occurrence of
visibletumors. In the light of our results, sarcoma formation might be
regarded as the disease end-stage of a MD in mice.
The finding of cancer-like genomic aberrations and DNA
damage in the skeletal muscle from MD-mice inspired us to search
for such aberrations in skeletal muscle of human MD patients. We
focused on DMD and LGMDs caused by DYSF, CAPN3,o rFKRP
mutations, representing the most frequent MDs, and found that all
of them are associated with somatic aneuploidy and widespread
DNA damage in skeletal muscle tissue in vivo. Also in vitro, cultured
myogenic stem cells from DMD and LGMD2B patients exhibited
DNA damage and aneuploidy. In our study, somatic aneuploidy
appeared to be a feature concurring with the outbreak of
pathology in dystrophic muscle and to increase with age in
human MD patients. In contrast, high levels of DSBs were already
evident in fetal muscle from DMD and MDC1C individuals and
in muscle biopsies from DMD infants (,1 year), which suggested
that DNA damage precedes the clinical manifestation and
therefore cannot be solely related to replication stress. While
somatic aneuploidy has been reported in multiple human
pathologies, such as Alzheimer’s disease, this is the first report
on gross somatic aneuploidy in MDs. Genomic instability has been
reported in laminopathy-based premature ageing [44], a condition
caused by mutations in lamin A/C, notably another MD-related
molecule. DNA damage was shown recently in Friedreich’s ataxia,
a neurodegenerative disorder [45].
Depending on the context, aneuploidy not only can promote
tumorigenesis [18,46–47], but also can impair proliferation, cause
premature replicative senescence [48], or can even suppress
tumorigenesis [49]. Under the assumption that aneuploidy affects
cells destined for muscle regeneration and/or function, aneuploidy
could therefore represent an important pathological feature causing
a propensity for malignant transformation in murine MDs and
contributing to tissue malfunction and diminished regenerative
capacity in human MDs. Unrepaired DNA damage activates
cellular senescence [50] and could therefore be also associated with
the known generalized diminished replicative capacity of DMD
myoblasts [51], contributing to the progressive exhaustion of the
muscle’s regenerative potential [52]. In the murine condition,
senescence could also underlie sarcoma susceptibility as secreted
senescence associated factors can contribute to a pro-tumourigenic
inflammatory environment [50], thereby promoting the occurrence
of age-related cancer [53]. In this context, it will be interesting to
study sarcoma formation in mdx mice lacking the RNA component
of telomerase (mdx/mTR) that have very recently been shown to
have shortened telomeres in muscle cells and a severe progressive
muscular dystrophy [52].
For the time being, we have no answer for why murine MDs
frequently end up in sarcoma formation while in human MD
patients increased muscle-tumor susceptibility has not been
reported. But it is interesting to note that it is also not fully
understood why loss of dystrophin causes a fatal MD in humans
while only a mild myopathy in mice. Also, Dysf
2/2 and Capn3
2/2
deficient mice are largely spared the severe symptoms of the patients
with LGMD due to defects in these two genes. We speculate,
however, that essential differences in tumor biology between men
and mice could account for this difference: while humans are prone
to epithelial carcinomas, mice commonly develop mesenchymal
sarcomas, which might be due to profound differences in telomere
biology between the two species [54]. Also, fewer genetic events are
required to induce malignant transformation in mice compared to
humans [43,55].
Concluding remarks
Collectively, our findings that genetically distinct MDs in mice
and humans share a common molecular pathology characterized
by DNA damage and genomic instability similar to pre-cancerous
lesions suggests the existence of a novel, unifying pathomechanism
that might contribute to disease progression through erosion of the
replicative capacity of muscle stem cells and could therefore help
to explain the common fatal progression of degeneration and
wasting in MD. This is a novel aspect, which contributes to our
understanding of MD, and moves an orphan disease close to the
common disease cancer, thereby hopefully opening novel
therapeutic avenues.
Materials and Methods
Patients and muscle tissue biopsies
Samples for this study were collected from diagnostic skeletal
muscle biopsies, which had been conducted in patients assigned for
evaluation of musculoskeletal disorders at our department. Patients or
their legal guardians gave informed consent for scientific purpose use
of left-over tissue samples. DMD patients included in this study had a
confirmed molecular diagnosis of DMD, ascertained by lack of
dystrophin staining in immunohistochemistry (IH) and Western Blot
(WB), and in most cases a genetic diagnosis. Muscle biopsy samples
used in this study were from a total of n=6 different DMD patients:
M2006 (age at muscle biopsy: 9 m; DMD gene mutation:
c.3053_3087del), M2008 (11 m; c.8669-1G.T), M1633 (6 a;
c.858T.G p.Tyr286X), M1994 (7a; unknown DMD mutation),
M1895 (8 a; dup_ex3-7), M1959 (15 a; del_ex17), and two samples
from aborted fetuses with DMD. LGM2DA patients (n=3) had a
genetic diagnosis and WB exhibited absence of calpain-3 specific
bands in muscle tissue: M1883 (9 a; c.550delA p.Thr184ArgfsX36),
M2207 (13 a; c.550delA), M2219 (25 a; c.1342C.T p.Arg448Cys).
LGMD2I patients (n=3) had a confirmed diagnosis by FKRP gene
sequencing: M1787 (10 a; c.854A.C p.Glu285Ala), M2190
(28 a; c.826C.A, p.Leu276Ile), M2166 (prenatal; c. [962C.A]+
[1086C.G] p.Ala321Glu + p.Asp362Glu). LGMD2B in one patient
was confirmed by reduced dysferlin reactivity in IH and WB, and
DYSF gene sequencing: M2057 (62 a, c.509C.A p.Ala170Glu). All
tissue samples were snap-frozen in dry ice-cooled 2-methylbutane
within 1 h after biopsy and stored at -80uCu n t i lu s e .
Myoblasts
Primary myoblast cultures were obtained from the Muscle
Tissue Culture Collection, Friedrich-Baur-Institute, Department
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many). DMD: ‘‘Essen 88/07’’ (14 a, del45_50); ‘‘72/05’’ (7 a,
dup_ex8-29); ‘‘Essen 8/02’’ (4 a, del_ex51-55); ‘‘166/00’’ (6 a,
2bp-deletion in exon 6); LGMD2B: ‘‘90/01’’ (36 a, female, c.
[638C.T]+ [5249delG]); ‘‘176/01’’ (32 a, male, c. [2367C.A]+
[5979dupA]); ‘‘362/03’’ (male, 33 a, c. [exon 5 p.Pro134Leu]+
[5022delT]); controls: ‘‘363/07’’ (21a, male); ‘‘179/07’’ (21a,
female). Cells were maintained in Ham’s F-12 medium supple-
mented with 15% fetal bovine serum, GlutaMax (L-glutamine
200 mM), glucose (6.6 mM), fetuin (0.47 mg/mL), bovine serum
albumin (0.47 mg/mL), dexamethasone (0.38 mg/mL), insulin
(0.2 mg/mL), epidermal growth factor (10 ng/mL), Pen-Strep
(penicillin G 5000 units/mL, streptomycin 5 mg/mL), and
fungizone (amphotericine B 0.5 mg/mL) at 37uC in a humidified
atmosphere of 5% CO2: 95% air. For experimental purposes, cells
were harvested after 3 or 4 passages. DNA was isolated using the
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to
the manufacturer’s recommendations. RNA was isolated using
TRI Reagent (Sigma-Aldrich, St. Louis, MO). Cells were stained
with BD Cycletest Plus, DNA Reagent Kit for DNA content
analysis by flow cytometry (BD Biosciences, San Jose, CA).
Mice
Mice stocks were maintained at the Division for Laboratory
Animal Science and Genetics (Medical University Vienna,
Himberg, Lower Austria) under institutionally approved protocols
for the humane treatment of animals. Mice were cared for in our
facilities under conventional housing conditions and received food
and tap water ad libitum. Mice presenting with weakness received
intensive care, were fed with food pellets soaked in tap water, and
were examined daily. Aged mice were checked daily for the
development of tumors. In general, tumors were characterized by
rapid growth, necessitating the killing of affected mice within few
days after visual identification of sarcomas. The Dmd
mdx C57BL/
10 (mdx), Dmd
mdx-3cv C57BL/6 (mdx-3cv), SJL Dysf
im (SJL-Dysf), and
B6C3Fe Large
myd (myd) mice were originally obtained from The
Jackson Laboratory (Bar Harbor, ME). To study dystrophin
deficiency on other strains, we inbred the Dmd
mdx mutation to C3H
and BALB/c (.20 consecutive backcross generations; residual
heterozygosity ,0.01). Some mdx mice were maintained on a
mixed C57BL/6 x BALB/c background. Further, we inbred the
SJL-Dysf mutation onto the C57BL/10 background, where a
prolonged life span compared to SJL was observed, which enabled
us to study late-onset stages of dysferlin-deficiency. Capn3 knockout
mice (Capn3
tm1Jsb) [11] on the 129/Sv x C57BL/6 background
were obtained from Isabelle Richard and crossed to C57BL/6
mice. To generate Dmd
2/2 Dysf
2/2 and Dmd
2/2 Capn3
2/2
double-mutants, mdx mice were crossed to SJL-Dysf (C57BL/10)
and Capn3 knockout mice. Some mdx C57BL/10, mdx-3cv C57BL/
6, as well as SJL-dysf C57BL/10 mice were crossed to B6C3Fe myd
mice. Of these animals, only Large+/2 and Large+/+ mice were
used for analysis of tumorigenesis, which were indistinguishable
from pure mdx, mdx-3cv, and SJL-dysf mice, respectively. In all
cases, Large+/2 heterozygosity had no influence on tumorigenesis
and conferred no overt additional phenotype with regard to
muscle pathology. After sacrifice by cervical dislocation, mice were
dissected, and muscles, other tissues, and (where applicable)
tumors were excised and snap-frozen in dry ice-cooled 2-
methylbutane. All samples were stored at -80uC.
Tumor cell cultures
Using sterile techniques, parts of excised tumors were washed in
PBS, cut into small pieces, and cultured in primary medium,
containing DMEM (Dulbecco’s Modified Eagle’s Medium, 4.5 g/L
glucose; PAA Laboratories, Pasching, Austria), 20% fetal bovine
serum (FBS ‘‘GOLD’’ Origin: USA; PAA Laboratories), 200 U/l
PenStrep (Penicillin, Streptomycin; Lonza, Cologne, Germany) and
2.5 mg/ml Fungizone (Gibco, Invitrogen Ltd, Paisley, UK). After
sporadic adhesion of tumor cells, remaining tissue parts were
removed, and the primary medium was replaced by growth
medium (DMEM, 20% FBS, 50 U/l PenStrep). To activate
differentiation, FBS was replaced by 2% horse serum (PAA
Laboratories). DNA/RNA extraction was performed as described
above for cultured myoblasts.
DNA and RNA isolation from mouse tissues
DNA was isolated from serial 5 mm-cryosections prepared from
dissected skeletal muscle (,5 mg) or tumor (,10 mg) specimens.
Reference sections from the sampling procedure were HE-stained
for histomorphological examination. Sections were stored at
280uC and then subjected to tissue lysis and nucleic acid
purification according to the QIAamp DNA Mini Kit protocol
(Qiagen). Mouse tail DNA was isolated using the same protocol
starting from lysates prepared by directly lysing 2–3 mm tail tips.
DNA concentrations were measured using the NanoDrop
spectrophotometer (Peqlab, Erlangen, Germany), DNA samples
were diluted (10 ng/ml) and stored at 220uC until use. RNA was
extracted from serial 10 mm-cryosections by lysis in 1 TRI
Reagent (Sigma-Aldrich), chloroform extraction, and precipitation
with isopropanol. RNA samples were measured by spectropho-
tometry (NanoDrop) and quality controlled using BioAnalyzer
LabChips (Agilent Technologies, Santa Clara, CA).
Histology and immunohistochemistry
Cryosections were stained with haematoxylin and eosin (HE).
Sudan Black B was used for lipid staining. For immunohisto-
chemistry, 10 mm cryosections were fixed using 3.7% paraformal-
dehyde (5 min), treated with 0.1% Triton-X100 (5 min), rinsed in
PBS, and subsequently incubated with primary antibodies. For
immunocytochemistry, cytospins were prepared from cell suspen-
sions and subjected to methanol/acetic acid (3:1) fixation before
antibody incubation. Primary antibodies used in this study were as
follows: Myogenin (Santa Cruz Biotechnology, CA; sc-576), Myf-5
(sc-302), desmin (Millipore, Billerica, MA, MAB3430), Cdk4 (sc-
260), PCNA (sc-7907), p27 (sc-776), p-Ser1981-ATM (Cell
Signaling Technology, Danvers, MA; #4526), phopsho-Ser428-
ATR (#2853), p-Ser296-Chk1 (#2349), p-Thr68-Chk2 (#2661),
p-Ser139-Histone H2A.X (#9718). Secondary antibodies were
conjugated to Alexa-Fluor 488, Alexa-Fluor 594 (Molecular
Probes Invitrogen, Carlsbad, CA), Cy3 (Dianova, Hamburg,
Germany), or to horseradish peroxidase. Where indicated,
immunostained sections were counterstained with 49,6-diamidino
-2-phenylindole (DAPI) and then analyzed by confocal microscopy
using either Olympus Fluoview or Zeiss Axioplan2 microscopes.
Fully automated software-assisted quantification of DNA damage
(c-H2A.x foci) in myoblasts was performed using the software
Metafer (MetaSystems, Altlussheim, Germany). Graphical repre-
sentations (plots of fluorescence intensity versus foci numbers) were
generated in R.
Array comparative genomic hybridization (aCGH)
Matched pairs of sarcoma and tail-tip DNA (as reference)
samples from the same mice were analyzed using the Agilent
mouse genome CGH 44K (design ID 015028) and 244K (014695)
oligonucleotide microarrays (Agilent Technologies). Human
myoblast DNA samples were analyzed on Agilent human genome
CGH 44K arrays (014950), using as reference human genomic
DNA from multiple anonymous male donors that was purchased
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procedures were performed according to the instructions provided
by Agilent. In brief, 200 ng of test and reference DNA were
digested with AluI and RsaI (both Promega) and then subjected to
differential labeling by random priming with incorporation of
either Cyanine 3- or Cyanine 5-dUTP (PerkinElmer, Waltham,
MA) using the BioPrime Array CGH Genomic Labeling System
(Invitrogen, Carlsbad, CA). After purification with Microcon YM-
30 centrifugal filter units (Millipore), the labeled products were
combined, mixed with blocking agent, Hi-RPM hybridization
buffer (both included in the Oligo aCGH/ChIP-on-Chip
Hybridization Kit, Agilent), human Cot-1 DNA (Roche Diagnos-
tics, Mannheim, Germany) or mouse Cot-1 DNA (Invitrogen), and
hybridized onto respective microarray slides. Hybridization was
carried out for 48 h at 65uC in a hybridization oven. Slides were
washed according to the protocol by Agilent, scanned using the
Agilent Technologies Scanner G2505B and analyzed using the
Feature Extraction and Genomic Workbench 5.01 (formerly DNA
Analytics 4.0) software.
Quantitative PCR (qPCR)
To screen for Met (chromosome [chr] 6) and/or Jun (chr 4) as
well as Cdk4 and/or Mdm2 (chr 10) oncogene amplification, tumor
DNA samples (25 ng) were subjected to a quantitative endpoint
PCR, consisting of 0.4 mM each primer, 0.2 mM dNTPs, 1.5 mM
MgCl2, (NH4)2SO4-containing amplification buffer, and 0.5 units
Taq DNA polymerase (reagents from Fermentas, St. Leon-Rot,
Germany). Competitive co-amplification of internal control targets
(with similar amplicon size) allowed the unambiguous determina-
tion of $4-fold amplification levels. Primer sequences (59-.39)
were as follows: Met_f AAC TGT TCT TGG AAA AGT GAT
CGT; Met_r TTT GAA ACC ATC TCT GTA GTT GGA;
S100a8_f CGT TTG AAA GGA AAT CTT TCG TGA;
S100A8_r TAT CCA GGG ACC CAG CCC TA; Jun_f AAA
GCA GAC ACT TTG GTT GAA AG; Jun_r CGC TAT TAT
AAA TAT GCA CAA GCA A; Mdm2_f CAT CGC TGA GTG
AGA GCA GA; Mdm2_r AAG ATG AAG GTT TCT CTT
CTG GTG; Cdk4_f AGT TTC TAA GCG GCC TGG AT;
Cdk4_r TCT CTG CAA AGA TAC AGC CAA C; Lig3_f AGG
AGA GAA GCT GGC TGT GA; Lig3_r AGC TTT CCT TCC
TCT TTG CC. After cycling (3 min 95uC, 306 [40 sec 95uC,
40 sec 60uC, 1 min 72uC], 3 min 72uC), 5 ml aliquots of reaction
products were analyzed on ethidium bromide-stained 1.5%
agarose gels and quantified from captured images using Image J.
Relative Met, Jun, Cdk4, and Mdm2 copy number levels were
calculated by normalization to the internal standard (S100a8 on
chr3 and Lig3 on chr11, respectively). Tumor samples with copy
numbers indicating oncogene amplification were also subjected to
verification by real-time PCR (see below). Deletions at the Cdkn2a
(chr 4) and Nf1 (chr 11) loci were measured using a quantitative
real-time PCR (qRT-PCR) SybrGreen assay (DCt method),
involving separate amplification of target genes and an internal
reference (Lig3). Primers were designed for Cdkn2a exon 2, which
encodes parts of both p16
INK4a and p19
ARF. CGH 244K data
from one Dysf
-/- tumor revealed a compound loss at the Nf1 locus
consisting of a large ,0.4 Mbp deletion encompassing the whole
gene and a smaller ,42 kb deletion spanning exons 9–28. To
screen for Nf1 deletions in other tumors, two different exons (23
and 56) were chosen as qRT-PCR targets. Primer sequences were
as follows: Cdkn2a_f: GTA GCA GCT CTT CTG CTC AAC
TAC; Cdkn2a_r AAT ATC GCA CGA TGT CTT GAT GT;
Nf1_I22_f TGA TGA AGT AGT TTG CCA TTG TTT;
Nf1_E23_r TTG CCA TCA TGA CTT CAA CTA ACT;
Nf1_I55_f CTC TCG CTC TTC ATT TCA TCT TCT;
Nf1_E56_r GCC ATA AGC CAT TAA AAC CAA AAC. Met
and Jun targets were the same as above. 15 ng of DNA template
were amplified in the presence of 0.5 mM primers and components
of the SensiMixPlus SYBR universal mix (Quantace, London,
UK) using the Stratagene Mx3005P cycler (Agilent). Cycling
conditions: 10 min 95uC, 406[40 sec 95uC, 40 sec 60uC, 1 min
72uC], followed by a dissociation segment for melting curve
analysis. Chromosome 8 and 15 gains were also assessed by qRT-
PCR choosing Junb (chr 8) and Myc (chr 15) as targets, respectively.
Gene dosage was normalized to an arbitrary gene on chr 12
(Prima1), whose copy number appeared widely stable in the CGH
screen. Primer sequences were as follows: Junb_f GCA GCT ACT
TTT CGG GTC AG; Junb_r GTG GTT CAT CTT GTG CAG
GTC; Myc_f CCA CCT CCA GCC TGT ACC T; Myc_r GTG
TCT CCT CAT GCA GCA CTA; Prima1_f GTT TCC ATA
TCT GCA GGT GAC A; Prima1_r CTC TCG TTC ATC AGC
TGT TCC T. Reactions were carried out as above but with 30 sec
extension steps. Fluorescence data were analyzed using the MxPro
4.1 software (Stratagene). After verification of primer perfor-
mance, relative quantification was obtained using the threshold
cycle method; DCt values were calibrated to wild-type (C57BL/10)
tail-tip DNA. Plots of DDCt (sarcomas) values were done in R and
graphical representations of DCt values from skeletal muscle DNA
samples were made in Microsoft Excel 2007.
Reverse transcriptase PCR (RT-PCR)
To study whether mixed sarcomas from MD-mice express select
human sarcoma-related genes, we subjected RNA isolated from
primary tumor samples as well as from tumor cell cultures to
quantitative RT-PCR. Total RNA (1 mg) was reverse-transcribed
by standard oligo-dT primed cDNA synthesis using M-MuLV
Reverse Transcriptase in a reaction buffer containing 50 mM
Tris-HCl (pH 8.3 at 25uC), 50 mM KCl, 4 mM MgCl2,1 0m M
DTT, and 1 mM dNTPs (Fermentas). An aliquot corresponding
to 10 ng of the initial RNA sample was subjected to a quantitative
endpoint PCR, consisting of 0.4 mM each primer, 0.2 mM
dNTPs, 2 mM MgCl2, (NH4)2SO4-containing amplification
buffer, and 0.25 units DreamTaq Green DNA Polymerase
(reagents from Fermentas) in a 25 ml reaction volume. Primer
sequences for the human rhabdomyosarcoma-marker genes (Myog,
Myl4, Igf2, Prox1), a fibrosarcoma gene (Vcan), and liposarcoma-
related genes (Pparg, Myo1e, Hoxa5, Plau) are available from the
authors on request. After cycling (3 min 95uC, 356[20 sec 95uC,
20 sec 60uC, 40 sec 72uC], 3 min 72uC), 10 ml aliquots of reaction
products were analyzed on ethidium bromide-stained 1.5%
agarose gels and quantified from captured images using Image J.
Relative RNA abundance was calculated by normalization to the
Gapdh transcript levels and compared to skeletal muscle samples
isolated from wild-type and mdx mice. RNA abundance in tumor
cell lines was compared to murine C2C12 myoblast cells.
Visualization of gene expression was accomplished by heatmaps
made in R using the heatmap.2 function.
Interphase fluorescence in situ hybridization (I-FISH)
For I-FISH experiments on myoblasts, cells were fixed using 4%
formaldehyde. FISH analysis on interphase nuclei extracted from
cryofixed tissues was performed according to a previously
published protocol with modifications [56]. In brief, thirty
20 mm-cryosections were fixed in PBS-buffered 4% paraformal-
dehyde (2–3 h at ambient temperature), rinsed twice with 0.9%
NaCl and stored at 4uC overnight until further use. Fixed tissue
sections were then transferred into a 90 mm nylon mesh and
subjected to proteinase K digestion (0.05%; 10–15 min 37uC).
After harvesting by cytospinning through the mesh, nuclei were
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washed with 16 PBS (263 min), pre-treated with sodium
thiocyanate (1 M, 80uC 1 min), and subjected to digestion with
proteinase K (1 min at 37uC). After fixation, slides were air-dried,
followed by heating to 78uC (8 min) for denaturing. Slides were
then incubated with digoxigenin or biotin labeled chromosome
probes (2p, 18cen, 19q from Dr. M. Rocchi, Molecular
Cytogenetic Resource Centre, Bari, Italy; chr1 from Dr. Howard
J. Cooke [57]; 8cen purchased from Kreatech Diagnostics,
Amsterdam, The Netherlands; chr13 FKHR and 19p/19q from
Vysis, Abbott Laboratories, IL) for hybridization overnight at
37uC. Slides were washed in 26 SSC 50% formamide, and 26
SSC at 42uC, and incubated with Cy3-labelled anti-biotin
(Dianova, Hamburg, Germany) or FITC-labeled anti-digoxigenin
antibodies in 2% BSA for 30 min at 37uC in a humid chamber.
After washing in 46 SSC 0.1% Tween-20 (267 min at 42uC),
slides were incubated with secondary antibodies labeled with Cy3
or FITC (Dianova) in 2% BSA for 30 min at 37uC, washed again
as above, ethanol-dried, and mounted using Vectashield with
DAPI (Vector Laboratories, Burlingame, CA). Slides were
analyzed using an Axioplan2 (Zeiss) microscope and I-FISH
signals were captured using the ISIS software and quantification of
the I-FISH spots was achieved with the Metafer software (both
from, MetaSystems, Altlussheim, Germany). For each sample 300
nuclei were automatically detected by the software and subse-
quently visually inspected by two independent investigators. Data
presented were calculated from an average of 200 nuclei eligible
for analysis.
Supporting Information
Figure S1 Expression of myogenic and human sarcoma
biomarker genes in murine MD mixed sarcomas. To study
whether mixed sarcomas from MD-mice express select human
sarcoma-related genes (rhabdomyosarcoma-marker genes: Myog,
Myl4, Igf2, Prox1, a fibrosarcoma gene: Vcan, and liposarcoma-
related genes: Pparg, Myo1e, Hoxa5, Plau), we subjected RNA
isolated from primary tumor samples as well as from tumor cell
cultures to quantitative RT-PCR. The figure shows a heatmap
representation of expression levels corresponding to human
sarcoma-related genes, revealing high abundance of not only
rhabdomyosarcoma (Rhabdo) marker genes but also of genes
related to human fibrosarcoma (Fibro) and liposarcoma (Lipo) in
both, primary sarcomas (A) and in vitro tumor cell cultures (B).
(PDF)
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